Welcome to our dedicated page for Arrowhead Pharma SEC filings (Ticker: ARWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents give detailed insight into Arrowhead’s RNA interference (RNAi) pipeline, capital structure, collaborations, and material events affecting ARWR stock.
Arrowhead’s filings include Form 8-K current reports describing key developments such as approvals for REDEMPLO (plozasiran) in familial chylomicronemia syndrome, Breakthrough Therapy designation for investigational plozasiran in severe hypertriglyceridemia, interim clinical data for obesity candidates ARO-INHBE and ARO-ALK7, and the initiation of a Phase 1/2a study of ARO-MAPT for tauopathies including Alzheimer’s disease. Other 8-Ks outline collaboration agreements, such as the exclusive license with Novartis for ARO-SNCA, and agreements involving Visirna Therapeutics and Sanofi in Greater China.
Filings also cover Arrowhead’s capital markets transactions, including underwriting agreements for public offerings of common stock, pre-funded warrants, and 0.00% convertible senior notes due 2032. These documents describe offering terms, use of proceeds for research and development, clinical trials, commercialization activities, and related capped call transactions intended to manage potential dilution upon note conversion.
On Stock Titan, Arrowhead’s SEC filings are updated in near real time from EDGAR. Users can review annual and quarterly reports when available, as well as current reports and exhibits that detail licensing deals, clinical milestones, and regulatory actions. AI-powered summaries help explain complex sections of 10-Ks, 10-Qs, and 8-Ks in plain language, and specialized views make it easier to track insider-related disclosures and other material information relevant to ARWR investors.
The Vanguard GroupSchedule 13G/A reporting its holdings in Arrowhead Pharmaceuticals Inc.. The filing states amount beneficially owned: 0 shares and percent of class: 0%. It explains an internal realignment on January 12, 2026 and that certain Vanguard subsidiaries now report holdings separately, in accordance with SEC Release No. 34-39538 (January 12, 1998).
Arrowhead Pharmaceuticals reported results of its 2026 annual stockholder meeting. Stockholders elected seven directors to the board, with vote totals for each nominee ranging from about 70.4 million to 100.8 million votes in favor.
Stockholders rejected the advisory Say-on-Pay proposal, with 41,625,740 votes for and 59,963,903 votes against, signaling dissatisfaction with executive compensation. They approved the Amended and Restated 2021 Incentive Plan and ratified KPMG LLP as independent auditors. As of the January 22, 2026 record date, 140,010,690 common shares were outstanding and entitled to vote.
Arrowhead Pharmaceuticals' Chief Medical Officer sells shares under a preset plan. Chief Medical Officer James C. Hamilton executed an open-market sale of 10,000 shares of Arrowhead Pharmaceuticals common stock at a weighted average price of $64.19 per share on March 5, 2026, under a Rule 10b5-1 trading plan. After this transaction, he directly owned 236,958 shares, which include previously reported restricted stock units that remain subject to vesting conditions.
ARWR filed a Form 144 reporting a proposed sale of 10,000 common shares to be sold through Merrill Lynch (75 Rockefeller Plaza). The filing lists an aggregate value of $641,870.05 and a transaction date of 03/05/2026. The notice identifies the sale reason as Compensation with an effective date of 01/05/2025.
The filing also records prior sales: James Hamilton sold 40,164 common shares on 01/05/2026 for $2,534,478.03, listed under "Securities Sold During The Past 3 Months."
Arrowhead Pharmaceuticals, Inc. reported a sharp turnaround for the quarter ended December 31, 2025, with revenue of $264.0 million driven mainly by collaboration payments, compared with $2.5 million a year earlier. Net income attributable to the company was $30.8 million, versus a loss of $173.1 million.
Results were boosted by $229.5 million in revenue from Sarepta milestones and research, and $34.2 million from a new Novartis collaboration. Arrowhead ended the quarter with $201.6 million in cash, cash equivalents and restricted cash and $715.0 million in available-for-sale securities. The FDA approved REDEMPLO for Familial Chylomicronemia Syndrome, giving the company its first commercial RNAi product.
Arrowhead Pharmaceuticals, Inc. filed a current report to note that it has announced and discussed its fiscal 2026 financial results for the period ended December 31, 2025. These results were shared through a press release dated February 5, 2026.
The press release is provided as Exhibit 99.1 and is designated as “furnished” rather than “filed,” which limits its use in certain legal contexts. The company also included an Inline XBRL cover page data file as Exhibit 104, signed on behalf of Arrowhead by Chief Financial Officer Daniel Apel.
Arrowhead Pharmaceuticals is asking stockholders to approve several items at its virtual annual meeting on March 19, 2026, including board elections, a say-on-pay vote, ratification of KPMG as auditor, and an amended 2021 Incentive Plan. The plan would add 10,500,000 shares for equity awards and extend the plan term to January 2036, supporting long‑term stock-based compensation for employees, directors, and advisors.
The proxy highlights a majority‑independent board with a lead independent director, fully independent key committees, and a focus on environmental, social, and cybersecurity oversight. It also describes 2025 business achievements, including FDA approval of REDEMPLO for familial chylomicronemia syndrome, additional regulatory approvals abroad, major R&D and partnering milestones, and capital raises through convertible notes, common stock, and pre‑funded warrants totaling $930 million.
BlackRock, Inc. has filed an amended Schedule 13G reporting a large passive stake in Arrowhead Pharmaceuticals Inc.. As of 12/31/2025, BlackRock reports beneficial ownership of 20,323,221 shares of Arrowhead common stock, representing 15.0% of the outstanding class. BlackRock has sole voting power over 20,124,285 shares and sole dispositive power over 20,323,221 shares, with no shared voting or dispositive power.
The filing aggregates holdings across certain BlackRock business units and notes that one holder, iShares Core S&P Small-Cap ETF, on its own holds more than five percent of Arrowhead’s common stock. BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Arrowhead.
Arrowhead Pharmaceuticals issued $700,000,000 of 0.00% Convertible Senior Notes due 2032. These unsecured senior notes carry no regular interest and mature on January 15, 2032, with noteholders able to convert earlier under specified conditions and freely from October 15, 2031 until shortly before maturity.
The initial conversion rate is 11.4844 shares per $1,000 principal amount, implying an initial conversion price of about $87.07 per share, subject to customary adjustments and potential increases after certain make‑whole events. Arrowhead may redeem the notes on or after January 16, 2029 if its share price exceeds 130% of the conversion price for defined trading periods, and holders can require repurchase after specified fundamental changes.
In connection with the offering, Arrowhead entered into capped call transactions that cover the shares underlying the notes. The capped calls cost approximately $47.9 million and have an initial cap price of about $119.33 per share, which is described as an 85.0% premium to the public offering price in a concurrent equity offering, aiming to limit dilution and/or offset cash paid above principal on conversion.